[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"relapsed\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:relapsed":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100261018","identify-barriers-to-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-with-newly-diagnosed-and-relapsed-acute-leukemia-100261018",false,"NCT02677064","Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia","Observational Study to Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia, Myelodysplastic Syndrome and Myelproliferative Neoplasms","Inclusion Criteria:\n\n* Patients with newly diagnosed or relapsed acute leukemia. Patients undergoing reinduction due to primary induction failure are also eligible. Patients with acute leukemia will be enrolled to Arm A\n* Patients with diagnosis of MDS, MPN and MDS\u002FMPN overlap who meet any of the following criteria (based on NCCN guidelines):\n* Clinically significant cytopenia of at least 2 cell lines affected; Hgb\\\u003C10,\n* Platelet\\\u003C100,000, absolute neutrophil count\\\u003C1000\n* Bone marrow blasts \\>5% and any level of circulating blasts\n* Evidence of disease progression or no response to hypomethylating agents\u002Fimmunosuppressive treatment or a clinical trial.\n* IPSS Intermediate-1 and higher\n* IPSS-R intermediate and higher\n* All cases of therapy related MDS with excess blasts\n* In patients with Myelofibrosis: Low risk disease by DIPSS with either refractory, transfusion dependent anemia, circulating blasts cells greater than 2%; or adverse cytogenetics and any patient with DIPSS-intermidiate 1 and higher.\n* Patients with acute leukemia or MDS\u002FMPN who relapse after first allografts. Patients with post-transplant relapse will be enrolled to Arm C.\n* Patients 18 years of age or older and 80 years of age or younger\n* For the purposes of this protocol \"relapse\" is defined as re-emergence of the initial abnormal myeloid blast population (or blast equivalent) comprising 5% or more of marrow WBC or any amount prompting a therapeutic intervention targeting relapsed disease, including, but not limited to withdrawal of immunosuppression, targeted therapies, chemotherapy, etc.\n\nExclusion Criteria:\n\n* Patients with polycythemia vera (PV) and essential thrombocytosis (ET)","ALL","18 Years","80 Years",{"count":20,"type":21},1365,"ESTIMATED","OBSERVATIONAL","The investigators are doing this research study to assess the percentage of patients receiving stem cell transplantation for the type of blood cancer you have. They want to know how many patients get a transplant and why some patients do get a transplant while others do not. Also they want to explore why some patients elect not to undergo stem cell transplantation, when it is recommended by their physicians.",[25,26,27],"Acute Leukemia","Newly Diagnosed","Relapsed",[29,30,31],"Allogeneic Hematopoietic Stem Cell Transplantation","Identify Barriers","16-024","RECRUITING","2026-01-16",{"date":35,"type":36},"2026-01-20","ACTUAL",{"date":38,"type":4},"2016-02",{"date":40,"type":21},"2027-02",{"name":42,"class":43},"Memorial Sloan Kettering Cancer Center","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100536493","multicenter-platform-type-clinical-study-of-refractoryrecurrent-acute-myeloid-leukemia-100536493","NCT06265545","Multicenter, Platform-type Clinical Study of Refractory\u002FRecurrent Acute Myeloid Leukemia","Inclusion Criteria:\n\n* 1\\. Patients with acute myeloid leukemia (except for acute promyelocytic leukemia) diagnosed by bone marrow cell morphology, immunology and genetics above are classified according to the French-British-American Collaboration diagnostic criteria (FAB criteria) and the World Health Organization diagnostic criteria (WHO2016 criteria).\n\n  2\\. Meet criteria for refractory\u002Frecurrent AML (except APL). The recurrence was morphological recurrence, excluding molecular recurrence. Except for simple extramedullary leukemia.\n\n  3\\. Age and gender are not limited. 4. Informed consent must be signed before the start of the study procedure, and the informed consent must be signed by the patient himself or his immediate family if he is 18 years old and above; For young patients under the age of 18, the legal guardian shall sign the informed consent. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the condition, the informed consent shall be signed by the legal guardian or the patient's immediate family.\n\nExclusion Criteria:\n\n1. Concurrent malignant tumors of other organs (patients requiring treatment).\n2. Participants considered unsuitable for inclusion by the researchers.",{"count":51,"type":21},120,"INTERVENTIONAL",[54],"NA","To study the optimal therapeutic strategies for salvage treatment of refractory\u002Frelapsed AML, and to clarify the effectiveness and safety of various salvage treatment options. A prospective, multicenter, platform-type study was conducted to explore the overall response rate, tolerability, and survival of patients with R\u002FR AML with different treatment regimens.",[57,58,27],"AML","Refractory",[57,58,27],"2025-08-01",{"date":62,"type":36},"2025-08-06",{"date":64,"type":36},"2024-02-22",{"date":66,"type":21},"2026-06-30",{"name":68,"class":43},"Institute of Hematology & Blood Diseases Hospital, China",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":52,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":69},"100572358","early-phase-1-a-dose-escalating-study-of-cd19cd22bcma-car-t-therapy-in-relapsed-refractory-multiple-myeloma-100572358","NCT06732232","A Dose Escalating Study of CD19\u002FCD22\u002FBCMA CAR-T Therapy in Relapsed\u002F Refractory Multiple Myeloma","A Dose Escalating Study of CD19\u002FCD22\u002FBCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed\u002FRefractory Multiple Myeloma","Inclusion Criteria:\n\n* Participants must meet all of the following criteria in order to be enrolled:\n\n  1. Understand and voluntarily sign an informed consent form (ICF) before conducting any research related evaluations\u002Fprocedures;\n  2. Age range: 18-75 years old;\n  3. Expected survival period is not less than 12 weeks;\n  4. ECOG score ≤ 2 points;\n  5. The bone marrow flow cytometry results showed positive BCMA antigen (including weak positive, moderate positive, and strong positive);\n  6. According to the IMWG criteria, a diagnosis of multiple myeloma with measurable lesions must meet at least one of the following criteria:\n\n     1. Serum M protein (SPEP) ≥ 5g\u002FL\n     2. 24-hour urinary M-protein excretion rate ≥ 0.2g (200mg)\n     3. Serum free light chain (sFLC) ≥ 100 mg\u002FL and abnormal free light chain ratio\n     4. The ratio of primitive plasma cells to immature plasma cells in bone marrow cytology examination is greater than 5%, or the flow cytometry detection of monoclonal plasma cells is greater than 5%\n  7. Those who have received treatment with at least three different mechanisms of action (including anti-CD38 monoclonal antibodies, protease inhibitors, immunosuppressants, etc.) but have failed, and have experienced relapse (within 12 months), difficulty in treatment, or intolerance to the last line treatment regimen, including primary difficulty in treatment (subjects who have not achieved minimal remission \\[MR\\] or developed disease progression \\[PD\\] during treatment) or secondary difficulty in treatment (subjects who develop disease progression within 60 days after completion of treatment);\n  8. There is no significant abnormality in lung function, and the oxygen saturation is greater than 92% in the absence of oxygen inhalation;\n  9. The blood biochemistry test results meet the following criteria:\n\n     1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN)\n     2. Total bilirubin ≤ 1.5 × ULN\n     3. 24-hour serum creatinine clearance rate ≥ 30 mL\u002Fmin\n     4. Lipase and amylase ≤ 2 × ULN\n  10. The blood routine test meets the following criteria:\n\n      1. Lymphocyte count\\>0.5 × 10 \\^ 9\u002FL\n      2. Neutrophil count ≥ 1.0 × 10 \\^ 9\u002FL\n      3. Hemoglobin ≥ 60g\u002FL\n      4. Platelets ≥ 40 × 10 \\^ 9\u002FL\n  11. Men with fertility and women of childbearing age must agree to use effective contraceptive measures from the signing of the informed consent form until 2 years after the use of the study drug. Women of childbearing age include premenopausal women and women within 2 years after menopause. The blood pregnancy test for women of childbearing age must be negative during screening.\n\nExclusion Criteria:\n\n* Any of the following situations cannot be selected as a subject:\n\n  1. Asymptomatic (smoking type) multiple myeloma;\n  2. Multiple myeloma with only extramedullary lesions present;\n  3. Plasma cell leukemia;\n  4. Merge amyloidosis;\n  5. Central nervous system (CNS) metastasis, leptomeningeal disease, or metastatic central compression;\n  6. Pregnancy or lactation period;\n  7. Individuals who are HBsAg positive or HBcAb positive, unless HBV-DNA is less than 100 IU\u002Fml or below the minimum detectable value; Individuals who are positive for hepatitis C virus (HCV) antibodies and HCV-RNA; Individuals who are HIV antibody positive; Individuals who are positive for syphilis specific antibodies and have a positive TRUST (toluidine red unheated serum test) test; Individuals who test positive for Cytomegalovirus (CMV) DNA;\n  8. Cardiovascular diseases with clinical significance, including any of the following:\n\n     1. QT interval (QTcF) after heart rate correction:\\>470 milliseconds;\n     2. New York Heart Association Grade II and above heart failure;\n     3. Left ventricular ejection fraction (LVEF) ≤ 50%;\n     4. Poorly controlled hypertension (systolic blood pressure ≥ 150 mm Hg and\u002For diastolic blood pressure ≥ 95 mm Hg)\n     5. Arrhythmias that have clinical significance or require antiarrhythmic treatment (such as persistent ventricular tachycardia, ventricular fibrillation, apical torsion tachycardia, and complete left bundle branch block);\n  9. Has experienced unstable angina or acute myocardial infarction within the 6 months prior to signing the ICF;\n  10. Previously received any anti-CD45 or anti-CD3 treatment;\n  11. Individuals who are allergic to any of the components of the drugs used in this study, including but not limited to Qing Lin drugs (cyclophosphamide, fludarabine), etc;\n  12. Received any investigational drug or systemic anti-tumor treatment within 4 weeks (or 5 half lives of the drug, whichever the researcher deems more appropriate) prior to single collection;\n  13. History of other primary malignant tumors within 5 years prior to treatment, except for the following situations:\n\n      1. Fully treat cured cervical carcinoma in situ;\n      2. Localized basal cell carcinoma or squamous cell carcinoma of the skin;\n  14. Any uncontrolled active infection within 4 weeks prior to single collection requires parenteral antibiotics, antiviral or antifungal treatment;\n  15. Individuals with a history of active pulmonary tuberculosis infection within one year prior to single sampling (excluding subjects with a history of active pulmonary tuberculosis infection more than one year ago who, according to the researcher's judgment, currently have no evidence of active pulmonary tuberculosis);\n  16. Accompanying or having a history of interstitial lung disease or interstitial pneumonia;\n  17. Subjects who receive autologous hematopoietic stem cell transplantation (ASCT) within 8 weeks of signing the ICF, or who plan to undergo ASCT during the study period;\n  18. Subjects who have received allogeneic stem cell therapy in the past; The researchers believe that complications or other conditions in the subjects may affect their compliance with the protocol or make them unsuitable to participate in this study.","75 Years",{"count":79,"type":21},12,[81],"EARLY_PHASE1","This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologouschimeric antigen receptor T (CAR-T) cells targeting CD19\u002FCD22\u002FBCMA in patients with relapsed\u002Frefractory multiple myeloma.",[27,58,84],"Multiple Myeloma",[86,87,88,89,90],"relapsed\u002Frefractory multiple myeloma","CAR-T","CD19","CD22","BCMA","2024-12-11",{"date":93,"type":36},"2024-12-13",{"date":95,"type":36},"2024-12-12",{"date":97,"type":21},"2027-12-12",{"name":99,"class":100},"Shanghai Cell Therapy Group Co.,Ltd","INDUSTRY"]